Funding for this research was provided by:
Abbott Laboratories (ANSW1701)
Received: 2 April 2020
Accepted: 22 February 2021
First Online: 16 March 2021
: The study protocol of the MEDPass Trial was submitted to the CEC of the Canton Bern, Switzerland, and approved on October 15, 2018, under the number 2018-01512. The CEC receives annual safety and interim reports. The trial protocol version 1.2. with the request for prolongation of the trial has been accepted on December 9, 2019, by the CEC. Informed consent is obtained at inclusion from all study participants.
: Not applicable.
: SK: SK has received honorariums from Abbott Nutrition and Fresenius Kabi.MV: MV has not received any honorariums.PS: The institution of PS has received unrestricted grant money unrelated to this project from Nestlé Health Science and Abbott Nutrition.KU: KU has not received any honorariums.AWS: AWS has not received any honoraria.ER: ER has no conflict of interest to declare.ABS: ABS has not received honorariums or research support.ZS: The institution of ZS received speaking honorariums and research support from Nestlé Health Science, Abbott Nutrition, and Fresenius Kabi.